Physician profile
Katherine Mitchell
NPI 1447475439
$7,363.48
in general payments reported to CMS, 2019-2025
63 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $686 · 2022: $1,291 · 2023: $1,522 · 2024: $2,219 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,016 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,016.24 |
| Education | $369.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $498.28 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| Incyte Corporation | $446.25 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $409.62 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Daiichi Sankyo INC. | $395.46 | 2021-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $382.04 | 2021-2025 | Tagrisso, Imfinzi, Enhertu |
| Genzyme Corporation | $368.27 | 2022-2025 | |
| Janssen Biotech, INC. | $352.10 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $306.33 | 2022-2025 | |
| Abbvie INC. | $296.42 | 2021-2025 | |
| Seagen INC. | $279.58 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Beigene USA, INC. | $235.00 | 2022-2024 | Brukinsa |
| Pfizer INC. | $219.91 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $215.58 | 2021-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $211.06 | 2022-2025 | Pomalyst, Reblozyl, Abecma |
| Amgen INC. | $165.06 | 2021-2023 | Lumakras |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $159.54 | 2023-2025 | Orserdu, Elzonris |
| Sobi, INC | $150.61 | 2022-2025 | |
| Genentech, INC. | $144.87 | 2024 | Itovebi |
| Gilead Sciences, INC. | $131.41 | 2024 | Trodelvy |
| Lilly USA, LLC | $115.31 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $105.39 | 2023-2025 | Fruzaqla, Entyvio, Ninlaro |
| Eisai INC. | $99.99 | 2021-2025 | |
| Geron Corporation | $97.14 | 2025 | Rytelo |
| Kite Pharma, INC. | $91.81 | 2021-2023 | Yescarta |
| Genentech USA, INC. | $87.59 | 2022-2024 | Venclexta |
| Glaxosmithkline, LLC. | $75.50 | 2021-2025 | Ojjaara |
| Blueprint Medicines Corporation | $73.42 | 2022-2024 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $65.23 | 2022-2025 | Monoferric, Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.88 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $64.28 | 2024 | |
| Coherus Oncology, INC. | $57.11 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $55.90 | 2023-2024 | Ultomiris |
| Kyowa Kirin, INC. | $55.47 | 2023-2025 | Poteligeo |
| Alnylam Pharmaceuticals INC. | $50.70 | 2022-2023 | Onpattro |
| Genmab U.S., INC. | $48.98 | 2022-2025 | Epkinly |
| Astellas Pharma US INC | $48.48 | 2024-2025 | Vyloy, Cresemba |
| Regeneron Healthcare Solutions, INC. | $48.27 | 2023 | Libtayo |
| Sun Pharmaceutical Industries INC. | $44.77 | 2023 | Yonsa, Odomzo |
| Array Biopharma INC | $42.28 | 2024-2025 | Lorbrena, Braftovi, Xalkori |
| Tersera Therapeutics LLC | $41.89 | 2023-2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $41.37 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $40.83 | 2023-2025 | Orgovyx |
| Mirati Therapeutics, INC. | $39.04 | 2023-2024 | Krazati |
| Pharmaessentia USA Corporation | $38.70 | 2022-2023 | Besremi |
| Novo Nordisk INC | $35.88 | 2023-2024 | |
| G1 Therapeutics, INC. | $35.35 | 2023 | Cosela |
| Ipsen Biopharmaceuticals, INC | $34.33 | 2022-2025 | Onivyde |
| Cti Biopharma Corp. | $32.49 | 2023 | Vonjo |
| Cumberland Pharmaceuticals, INC. | $25.19 | 2025 | Sancuso |
| Iovance Biotherapeutics, INC. | $23.20 | 2024 | Amtagvi |
| Adaptive Biotechnologies Corporation | $21.48 | 2024 | Clonoseq |
| Fennec Pharmaceuticals, INC. | $18.74 | 2024 | Pedmark |
| Apellis Pharmaceuticals, INC. | $18.66 | 2022 | |
| Karyopharm Therapeutics INC. | $17.73 | 2024 | Xpovio |
| Adc Therapeutics America, INC. | $17.06 | 2024 | |
| Rigel Pharmaceuticals, INC. | $16.43 | 2023 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $16.20 | 2024 | |
| Novocure INC. | $15.39 | 2024 | Optune Lua (Novottf-200t) |
| Taiho Oncology, INC. | $15.10 | 2024 | |
| Azurity Pharmaceuticals, INC. | $15.04 | 2025 | Vivimusta |
| Immunocore Limited | $14.69 | 2025 | Kimmtrak |
| Janssen Pharmaceuticals, INC | $14.56 | 2021 | |
| Servier Pharmaceuticals LLC | $14.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.